ENTRY       D12490                      Drug
NAME        Fazpilodemab (USAN/INN)
FORMULA     C6418H9916N1700O2029S43
EXACT_MASS  144643.2996
MOL_WEIGHT  144732.3732
SEQUENCE    (Heavy chain)
            EVQLVESGGG LVQPGGSLRL SCAASDFSLT TYGVHWVRQA PGKGLEWLGV IWSGGSTDYN
            AAFISRLTIS KDNSKNTVYL QMNSLRAEDT AVYYCARDYG STYVDAIDYW GQGTLVTVSS
            ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
            GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG
            PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYG
            STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE
            MTKNQVSLSC AVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLV SKLTVDKSRW
            QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
            (heavy chain)
            EVQLVESGGG LVQPGGSLRL SCAASGFTFT SNYISWVRQA PGKGLEWVGE IDPYDGDTYY
            ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCATGT DVMDYWGQGT LVTVSSASTK
            GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS
            LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF
            LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYGSTYR
            VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSREEMTKN
            QVSLWCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN
            VFSCSVMHEA LHNHYTQKSL SLSPGK
            (Light chain)
            DIVLTQSPDS LAVSLGERAT INCRASESVE SYGNRYMTWY QQKPGQPPKL LIYRAANLQS
            GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQQSNEDPW TFGQGTKVEI KRTVAAPSVF
            IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
            STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
            (light chain)
            DIQMTQSPSS LSASVGDRVT ITCRASQDVS TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS
            RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H95, H147-H203, H223-L218, H264-H324, H370-H428, H229-h225, H232-h228, h22-h96, h219-l214, h143-h199, h260-h320, h366-h424, L23-L92, L138-L198, l23-l88, l134-l194)
  TYPE      Peptide
EFFICACY    Hypoglycemic
  TYPE      Monoclonal antibody, bispecific antibody
COMMENT     Treatment of type 2 diabetes mellitus and non-alcoholic fatty liver disease
TARGET      KLB [HSA:152831] [KO:K22404]
            FGFR1 (CD331) [HSA:2260] [KO:K04362]
  PATHWAY   hsa04714(152831)  Thermogenesis
BRITE       Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               FGFR family
                FGFR1 (CD331)
                 D12490  Fazpilodemab (USAN/INN)
             Transporters
              Other transporters
               Auxiliary transport proteins (TC:8.A)
                KLB
                 D12490  Fazpilodemab (USAN/INN)
DBLINKS     CAS: 2517935-02-1
///
